{\rtf1\ansi\ansicpg1252\cocoartf949\cocoasubrtf430
{\fonttbl\f0\froman\fcharset0 TimesNewRomanPSMT;\f1\fswiss\fcharset0 ArialMT;}
{\margl1800\margr1600\margt500\margbl1440}
{\pard\sa900\fs50\f0\i Media Release\par}
{\pard\f0\li0\ri0\sa360\sl360\fs22 Basel, 06. June 2007\line \line {\b Roche 
recalls Viracept due to chemical impurity} \line Patients are requested to contact their 
doctors to discuss alternative therapies\line \line \line Roche, in \u160?agreement 
and cooperation with Health Authorities (EMEA and Swissmedic), recalls in Europe and some other world 
regions all batches of Viracept powder and tablets. The US, Canada and Japan are not affected by this 
recall.\line \line Roche has received several reports that some batches of Viracept 
250 mg tablets have a strange odour. A detailed chemical analysis of the affected tablets showed they 
contain higher than normal levels of methane sulfonic acid ethylester. In the interest of patients safety 
Roche has decided to recall all batches of Viracept tablets and powder. \line \line Patients 
are requested to contact their doctors to discuss alternative therapies.\line \line {\b About 
Viracept} \line Viracept (nelfinavir), a protease inhibitor is supplied by Roche outside 
the US and Canada. Viracept was first introduced by Roche in 1998. \line \line {\b About 
Roche} \line Headquartered in Basel, Switzerland, Roche is one of the world\u8217?s leading 
research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As the world\u8217?s 
biggest biotech company and an innovator of products and services for the early detection, prevention, 
diagnosis and treatment of diseases, the Group contributes on a broad range of fronts to improving people\u8217?s 
health and quality of life. Roche is the world leader in in-vitro diagnostics and drugs for cancer and 
transplantation, a market leader in virology and active in other major therapeutic areas such as autoimmune 
diseases, inflammation, metabolism and central nervous system. In 2006 sales by the Pharmaceuticals 
Division totaled 33.3 billion Swiss francs, and the Diagnostics Division posted sales of 8.7 billion 
Swiss francs. Roche employs roughly 75,000 worldwide and has R&D agreements and strategic alliances 
with numerous partners, including majority ownership interests in Genentech and Chugai. Roche\u8217?s Diagnostics 
Division offers a uniquely broad product portfolio and supplies a wide array of innovative testing products 
and services to researchers, physicians, patients, hospitals and laboratories world-wide. For further 
information, please visit our website at www.roche.com (http://www.roche.com). \line \line \line {\pard\f0\li0\ri0\sa360\sl360\fs18 All 
trademarks used or mentioned in this release are protected by law.\line \line \par}\par}Viracept 
recall- Important advice to patients ( http://www.roche.com/med-cor-2007-06-06ba.pdf){\pard\f0\li0\ri0\sa360\sl360\fs22 For further 
information, also consult: www.roche-hiv.com (http://www.roche-hiv.com)\line \par}
{\pard \par}
{\pard\sb180\f1\fs22 {\b F. Hoffmann-La Roche Ltd}\line 4070 Basel\line Switzerland \par}
{\pard\sb180\f1\fs22 Corporate Communications\line Roche Group Media Relations \par}
{\pard\sb180\f1\fs22 Tel. +41 61 688 88 88\line Fax +41 61 688 27 75\line www.roche.com \par}
}